These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 3769387)

  • 41. Assessment of renal hemodynamic effects of nesiritide in patients with heart failure using intravascular Doppler and quantitative angiography.
    Elkayam U; Akhter MW; Liu M; Hatamizadeh P; Barakat MN
    JACC Cardiovasc Imaging; 2008 Nov; 1(6):765-71. PubMed ID: 19356514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Variable hemodynamic response to oral hydralazine in patients with refractory congestive heart failure.
    LeJemtel TH; Elkayam U; Ribner HS; Hellman C; Strom J; Frishman W; Strobeck J; Sonnenblick EH
    Eur Heart J; 1980 Jun; 1(3):157-63. PubMed ID: 7026250
    [No Abstract]   [Full Text] [Related]  

  • 43. Acute and long-term effects of nitrendipine on resting and exercise hemodynamics in essential hypertension.
    Nannan ME; Melin JA; Vanbutsele RJ; Lavenne F; Detry JM
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1043-8. PubMed ID: 6085364
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Central cardiac limit to aerobic capacity in patients with exertional pulmonary venous hypertension: implications for heart failure with preserved ejection fraction.
    Santos M; Opotowsky AR; Shah AM; Tracy J; Waxman AB; Systrom DM
    Circ Heart Fail; 2015 Mar; 8(2):278-85. PubMed ID: 25550438
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differences in the effects of alpha-1 adrenergic blockade with prazosin and indoramin on coronary blood flow during exercise.
    Bache RJ; Homans DC; Schwartz JS; Dai XZ
    J Pharmacol Exp Ther; 1988 Apr; 245(1):232-7. PubMed ID: 2896237
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alpha-adrenoreceptor blockade with indoramin in hypertension.
    Gould BA; Mann S; Davies AB; Altman DG; Raftery EB
    J Cardiovasc Pharmacol; 1983; 5(3):343-8. PubMed ID: 6191130
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Beneficial hemodynamic effects of intravenous terbutaline in patients with severe heart failure.
    Wang RY; Tse TF; Yu DY; Lee PK; Sum MS; Chow MS
    Am Heart J; 1982 Nov; 104(5 Pt 1):1016-21. PubMed ID: 7136991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 5-HT2-receptor blockade in the treatment of heart failure. A preliminary study.
    Demoulin JC; Bertholet M; Soumagne D; David JL; Kulbertus HE
    Lancet; 1981 May; 1(8231):1186-8. PubMed ID: 6112531
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of indoramin added to oxprenolol and bendrofluazide as a third agent in severe hypertension.
    Marshall AJ; Kettle MA; Barritt DW
    Br J Clin Pharmacol; 1980 Sep; 10(3):217-21. PubMed ID: 7437237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The cardiovascular effects of centrally and peripherally administered indoramin in conscious rats.
    Porter JP; Bonham AC; Mangiapane ML; Webb RL; Brody MJ
    Eur J Pharmacol; 1985 Feb; 109(1):9-17. PubMed ID: 3996469
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The acute and chronic effects of indoramin on renal function, hemodynamics, and transport.
    Morrison G; Spar B; Walker BR; Goldfarb S
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S25-9. PubMed ID: 2423792
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical cardiac electrophysiological assessment of indoramin.
    Butrous GS; Camm AJ
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S137-43. PubMed ID: 2423787
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of indoramin on finger circulation in patients with Raynaud disease.
    Clement DL; Duprez D; De Pue N
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S84-7. PubMed ID: 2423806
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antihypertensive therapy in the Federal Republic of Germany: clinical practice experience with indoramin (Wydora).
    Grube E; Giesing M
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S43-7. PubMed ID: 2423796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Indoramin in the treatment of hypertension: a placebo controlled trial.
    Ramirez J
    Curr Med Res Opin; 1976; 4(3):177-84. PubMed ID: 780059
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hemodynamic effects of isoxsuprine in cardiac failure.
    Gozo EG; Yebes RB
    Chest; 1984 Nov; 86(5):736-40. PubMed ID: 6488912
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antihypertensive therapy with indoramin in the elderly.
    Deitch MW; Allen IE; Pascucci VL
    J Cardiovasc Pharmacol; 1986; 8 Suppl 2():S88-92. PubMed ID: 2423807
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beneficial effects of the calcium antagonist PN 200-110 in patients with congestive heart failure.
    Broudy DR; Greenberg BH; Siemienczuk D
    J Cardiovasc Pharmacol; 1987 Aug; 10(2):190-5. PubMed ID: 2441170
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hemodynamic effects of diuresis at rest and during intense upright exercise in patients with impaired cardiac function.
    Stampfer M; Epstein SE; Beiser GD; Braunwald E
    Circulation; 1968 Jun; 37(6):900-11. PubMed ID: 5653053
    [No Abstract]   [Full Text] [Related]  

  • 60. Functional capacity of patients with chronic left ventricular failure. Relationship of bicycle exercise performance to clinical and hemodynamic characterization.
    Franciosa JA; Ziesche S; Wilen M
    Am J Med; 1979 Sep; 67(3):460-6. PubMed ID: 474591
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.